Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21919979 | 0.97 | MAP4K1 (0.43) | MAP4K1CYP3A4 | |
| SCHEMBL21920313 | 0.95 | MAP4K1 (0.43) | MAP4K1CYP3A4 | |
| SCHEMBL21919993 | 0.94 | MAP4K1 (0.39) | MAP4K1CYP3A4 | |
| SCHEMBL30087980 | 0.85 | MAP4K1 (0.42) | MAP4K1CYP3A4 | |
| SCHEMBL21919967 | 0.85 | MAP4K1 (0.42) | MAP4K1CYP3A4 | |
| SCHEMBL21919968 | 0.85 | MAP4K1 (0.42) | MAP4K1CYP3A4 | |
| SCHEMBL21920677 | 0.84 | MAP4K1 (0.32) | MAP4K1CYP3A4 | |
| SCHEMBL21919939 | 0.84 | MAP4K1 (0.50) | MAP4K1CYP3A4 | |
| SCHEMBL21921455 | 0.84 | MAP4K1 (0.50) | MAP4K1CYP3A4 | |
| SCHEMBL30087811 | 0.84 | MAP4K1 (0.50) | MAP4K1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| CN-113015526-A | Spirocyclic 2, 3-dihydro-7-azaindole compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| WO-2020061377-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | MAP4K1 36/4885CYP3A4 3696/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | MAP4K1 36/4885CYP3A4 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.